月別アーカイブ: 2014年12月

Checks 'distort' pharmacist role

Pharmacists have hit out at plans to make them responsible for checking whether patients are trying to dodge prescription charges.

The coalition has launched a drive to save £150 million by cracking down on fraud at chemists.

Under the proposals, a new IT system will allow staff to access Department for Work and Pensions records on the spot and see whether individuals are entitled to free prescriptions.

The existing retrospective checks by the NHS Business Services Authority are also being beefed up, with fraudsters facing fines of up to £2,500.

Meanwhile, a new team is being created to tackle fraud and error at dentists – with the aim of halving the £92 million a year bill by 2016.

Health Minister Dr Dan Poulter said: “We have a duty to ensure that every available penny of NHS cash is available for frontline patient care.

“This abuse of the NHS must stop. Claiming a free prescription when you are not entitled takes money away from other frontline patient services, and reduces the amount of money available to spend on patient care.

“We are taking action to ensure that people who are entitled to access free prescriptions, for the over 60s, are better supported to do so and we are getting tough on those who avoid paying their fair share.”

Chief pharmaceutical officer Dr Keith Ridge said: “These new measures aim to strike the right balance between encouraging the public to abide by the law, whilst ensuring healthcare professionals can meet their primary obligation to provide safe and effective care to their patients.”

But David Branford, board chair of the Royal Pharmaceutical Society (RPS), said: “This move to make pharmacists police the Government’s unfair charging system is totally unacceptable to us. We are opposed to any move that adds to the bureaucratic burden of pharmacists without improving patient safety in any way.

“We are concerned the Government is using provocative language to label those with incurable illnesses such as diabetes as ‘fraudsters’ just because they have forgotten to renew their medical exemption certificate. People need better access to their medicines, not a financial penalty for a minor mistake.

“We understand that the IT systems which are being deployed will allow pharmacists to check peoples’ benefit status in the pharmacy.

“We believe this will disrupt and distort the relationship between pharmacist and patient, impacting on the trust that currently exists and creating a culture of fear and uncertainty when asking for a prescription to be filled.”

Source Article from http://uk.news.yahoo.com/checks-distort-pharmacist-role-001816021.html
Checks 'distort' pharmacist role
http://uk.news.yahoo.com/checks-distort-pharmacist-role-001816021.html
http://news.search.yahoo.com/news/rss?p=pharmacist
pharmacist – Yahoo News Search Results
pharmacist – Yahoo News Search Results



Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug – Analyst Blog

Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. Regulatory updates include events like filing of investigational new drug applications and marketing applications, acceptance of these applications for review by the regulatory agencies, reviews by advisory panels and, finally, a response from the regulatory agency regarding the approval status.

Early last week, Kite Pharma, Inc. (KITE) provided a regulatory update on its lead candidate, KTE-C19. The company announced the submission of an investigational new drug application (IND) to the FDA for KTE-C19.

Kite Pharma intends to conduct a single-arm multi-center phase I/II study on KTE-C19 for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). In 2015, the company plans to initiate a phase I/II study on KTE-C19 for refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

Kite Pharma also has plans to conduct additional studies on KTE-C19 for other types of B-cell lymphoma and leukemia.

According to the National Cancer Institute, in 2014, 70,800 new patients have been diagnosed with NHL in the U.S. with 18,990 patients dying from the disease.

We note that KTE-C19 enjoys orphan drug status in the U.S. for the treatment of DLBCL. Additionally, the company intends to seek Breakthrough Therapy designation for the candidate for the treatment of aggressive NHL and some other types of cancer. Last month, KTE-C19 received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products for orphan medicinal product designation for the treatment of DLBCL. The opinion has been submitted to the European Commission for endorsement.

Since KTE-C19 leads Kite Pharma’s pipeline, we expect investor focus to remain on its development updates.

Kite Pharma carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech sector are Amgen Inc. (AMGN), The Medicines Company (MDCO) and Cytokinetics, Inc. (CYTK). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
MEDICINES CO (MDCO): Free Stock Analysis Report
 
AMGEN INC (AMGN): Free Stock Analysis Report
 
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
 
KITE PHARMA INC (KITE): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Source Article from http://finance.yahoo.com/news/kite-pharma-files-ind-non-222010390.html
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug – Analyst Blog
http://finance.yahoo.com/news/kite-pharma-files-ind-non-222010390.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Aoxing Pharmaceutical Company, Inc. Announces Appointment of CFO and Independent Director

JERSEY CITY, NJ / ACCESSWIRE / December 29, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) (“Aoxing Pharma” or “the Company’s”), a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotics and pain-management products, today announced the appointment of Mr. Wilfred Chow as Chief Financial Officer and Dr. Hui (David) Shao as independent director of the Company. Mr Guoan Zhang who has been serving in the role of Acting CFO, will continue to serve as the Company’s SVP for Finance. Our director, Mr. Zhimin Li, resigned from his position on the Board, effective December 31, 2014.

Mr. Wilfred Chow is joining Aoxing Pharma from Okeanos Capital Investment, a consulting firm focused on media and pharmaceutical. As managing director at Okeanos, Mr. Chow led corporate finance teams responsible for capital raises and M&A transactions. He led and completed two acquisitions and raised multiple rounds of capital from private equity funds for his clients. From 2010 to 2012, Mr. Chow was CFO of Tiger Media, Inc. (NYSE MKT: IDI), where he executed improvements in the company’s financial visibility and transparency to build long term shareholder value. Prior to IDI, Mr. Chow spent over 15 years working as SVP and CFO for venture-backed private and NYSE listed companies. Earlier in his career, Mr. Chow held a variety of position at PriceWaterhouseCoopers and Deloitte in both New York and Hong Kong. Mr. Chow earned a BS in Economics from Hong Kong University and a MBA from Leicester University.

Dr. David Shao served as Vice President of Finance and CFO of Aoxing Pharma from 2007 to 2010, and is joining our board in 2015. Dr. Shao is currently CFO of Yisheng Biopharma, a private equity backed pharmaceutical company focused on vaccines with operations in China. Prior to his employment by Aoxing Pharma, Dr. Shao was a Senior Analyst at Mehta Partners and Kamunting Street Capital Management in New York, where he was responsible for a healthcare investment portfolio of over $100 million across North American and European companies. Dr. Shao was a Principal Scientist, leading metabolic disease and oncology projects at Roche Pharmaceuticals, before he started his career on Wall Street. Dr. Shao was an independent director of Tongli Pharma from 2008 to 2011. Dr. Shao received his Ph.D degree in bioorganic chemistry at University of California, San Diego, and MBA degree in finance and accounting at Stern Business School of New York University.

Zhenjiang Yue, Aoxing Pharma’s Chairman and CEO, stated, “We are excited about these new additions to our Company, and believe we now have a stronger and more highly seasoned team in place to help accelerate our Company’s growth and increase our shareholders value. Wilfred brings considerable experience navigating the financial markets, especially in a multi-cultural setting. We believe he can help transform AXN into a more financially solid company and improve our communication with investors. In addition, the Company will greatly benefit from Hui Shao’s extensive experience in both the capital and pharmaceutical markets.”

About Aoxing Pharmaceutical Company, Inc.:
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.

For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.:
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “guidance”, “forecasted”, “projects”, “is expected”, “remain confident”, “will”, and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company’s filings with the Securities and Exchange Commission, specifically, Item 1A, “Risk Factors”, in the Form 10-K for the year ended June 30, 2014, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:
Vicky Zhang
646-367-1747
Investor.relations@aoxingpharma.com

Source: Aoxing Pharmaceutical Company, Inc.

Source Article from http://finance.yahoo.com/news/aoxing-pharmaceutical-company-inc-announces-134500047.html
Aoxing Pharmaceutical Company, Inc. Announces Appointment of CFO and Independent Director
http://finance.yahoo.com/news/aoxing-pharmaceutical-company-inc-announces-134500047.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results